BACKGROUND AND OBJECTIVES: Vascular calcification and endothelial dysfunction contribute to the development of cardiovascular disease in patients with chronic kidney disease (CKD). Sevelamer, a non-calcium-based phosphate binder, has been shown to attenuate cardiovascular calcification in CKD patients, although the exact mechanism has not been clarified. This study was designed to investigate the effect of short-term sevelamer treatment on both serum fetuin-A concentrations and endothelial dysfunction seen in CKD patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Fifty nondiabetic stage 4 CKD patients whose phosphate levels were > or =5.5 mg/dl were enrolled in this 8-wk randomized prospective study. Thirty-six healthy volunteers served as matched controls. Patients were treated with either sevelamer (n = 25, 12 males) or calcium acetate (n = 25, 13 males). Fetuin-A, high-sensitivity C-reactive protein, Ca x PO4 product, flow-mediated dilation (FMD), insulin, and homeostasis model assessment (HOMA) were obtained at baseline and after the treatment period. RESULTS: As expected, CKD patients had significantly lower levels of fetuin-A and FMD, and significantly higher levels of intact parathyroid hormone, Ca x PO4 product, and high-sensitivity C-reactive protein than controls (P < 0.001 for all). The use of sevelamer led to a significant increase in the fetuin-A concentration with improvement in FMD, whereas no significant difference was observed in the calcium acetate group. In a multiple regression analysis, FMD levels were independently related to fetuin-A both before (beta = 0.63, P < 0.001) and after (beta = 0.38, P = 0.004) treatment. CONCLUSIONS: This small, randomized, prospective study shows that short-term sevelamer treatment significantly increases fetuin-A levels and improves FMD in nondiabetic stage 4 CKD patients.
RCT Entities:
BACKGROUND AND OBJECTIVES:Vascular calcification and endothelial dysfunction contribute to the development of cardiovascular disease in patients with chronic kidney disease (CKD). Sevelamer, a non-calcium-based phosphate binder, has been shown to attenuate cardiovascular calcification in CKDpatients, although the exact mechanism has not been clarified. This study was designed to investigate the effect of short-term sevelamer treatment on both serum fetuin-A concentrations and endothelial dysfunction seen in CKDpatients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Fifty nondiabetic stage 4 CKDpatients whose phosphate levels were > or =5.5 mg/dl were enrolled in this 8-wk randomized prospective study. Thirty-six healthy volunteers served as matched controls. Patients were treated with either sevelamer (n = 25, 12 males) or calcium acetate (n = 25, 13 males). Fetuin-A, high-sensitivity C-reactive protein, Ca x PO4 product, flow-mediated dilation (FMD), insulin, and homeostasis model assessment (HOMA) were obtained at baseline and after the treatment period. RESULTS: As expected, CKDpatients had significantly lower levels of fetuin-A and FMD, and significantly higher levels of intact parathyroid hormone, Ca x PO4 product, and high-sensitivity C-reactive protein than controls (P < 0.001 for all). The use of sevelamer led to a significant increase in the fetuin-A concentration with improvement in FMD, whereas no significant difference was observed in the calcium acetate group. In a multiple regression analysis, FMD levels were independently related to fetuin-A both before (beta = 0.63, P < 0.001) and after (beta = 0.38, P = 0.004) treatment. CONCLUSIONS: This small, randomized, prospective study shows that short-term sevelamer treatment significantly increases fetuin-A levels and improves FMD in nondiabetic stage 4 CKDpatients.
Authors: Cristianne Tomiyama; Andrea Higa; Maria A Dalboni; Miguel Cendoroglo; Sergio A Draibe; Lilian Cuppari; Aluizio B Carvalho; Emilio M Neto; Maria Eugenia F Canziani Journal: Nephrol Dial Transplant Date: 2006-05-30 Impact factor: 5.992
Authors: Joachim H Ix; Glenn M Chertow; Michael G Shlipak; Vincent M Brandenburg; Markus Ketteler; Mary A Whooley Journal: Nephrol Dial Transplant Date: 2006-04-27 Impact factor: 5.992
Authors: Emiliana Ferramosca; Steven Burke; Scott Chasan-Taber; Carlo Ratti; Glenn M Chertow; Paolo Raggi Journal: Am Heart J Date: 2005-05 Impact factor: 4.749
Authors: Olivier Phan; Ognen Ivanovski; Thao Nguyen-Khoa; Nadya Mothu; Jesus Angulo; Ralf Westenfeld; Markus Ketteler; Natalie Meert; Julien Maizel; Igor G Nikolov; Raymond Vanholder; Bernard Lacour; Tilman B Drüeke; Ziad A Massy Journal: Circulation Date: 2005-11-01 Impact factor: 29.690
Authors: Jessica Kendrick; Emily Andrews; Zhiying You; Kerrie Moreau; Kristen L Nowak; Heather Farmer-Bailey; Douglas R Seals; Michel Chonchol Journal: Clin J Am Soc Nephrol Date: 2017-08-07 Impact factor: 8.237
Authors: Amy C Wilson; Elaine Urbina; Sandra A Witt; Betty J Glascock; Thomas R Kimball; Mark Mitsnefes Journal: Pediatr Nephrol Date: 2008-05-06 Impact factor: 3.714
Authors: Diana I Jalal; Emily Decker; Loni Perrenoud; Kristen L Nowak; Nina Bispham; Tapan Mehta; Gerard Smits; Zhiying You; Douglas Seals; Michel Chonchol; Richard J Johnson Journal: J Am Soc Nephrol Date: 2016-09-12 Impact factor: 10.121